Phase 2 N=19 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Metastatic Urothelial Cancer
Primary: Objective Response Rate (ORR) — 0 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=15 A Study of Soticlestat and Rifampin in Healthy Adults
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Soticlestat When Administered Alone and With Rifampin — 1364; 176.8 nanogram per milliliter (ng/mL)
N/A N=30 Controlling and Lowering Blood Pressure With The MOBIUS HD™ (CALM-FIM_EUR)
Hypertension
Primary: Number of Participants With Serious Adverse Events (SAEs) — 8 Participants
Phase 2 N=86 A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP]) at Day 14 — 6.04; 6.14; 5.92; 6.03 units on…
N/A N=382 Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization
Sickle Cell Disease
Primary: Mean Change in PDC From Baseline Through 24 Weeks — 16.3 percentage of days
Phase 2 N=123 Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Phase 2 N=40 A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules
Helicobacter Pylori Infection
Primary: The Eradication Rate of Helicobacter Pylori Infection — 0; 3; 4; 8 Participants
N/A N=61 A Cross-sectional Study to Measure Cough in Severe Asthma
Asthma · Cough
Primary: Cough Frequency Measurement — 6.6; 2.7; 2.5; 12.7 coughs per hour over a 24 hour monitorin
N/A N=31 The National Diabetes Prevention Program in Rural Communities
PreDiabetes · Weight Loss · Lifestyle Risk Reduction
Primary: Change in Body Weight From 0-6 Months — -6.0; -1.7 kilograms
N/A N=33 Diabetes Prevention Program in Youth
Pre Diabetes
Primary: Change From Baseline Hemoglobin A1c — -0.5 A1c percentage points
Phase 2 N=87 Effects of Vivatlac Baby on Crying Behavior of Colicky Babies
Infantile Colic
Primary: Number of Participants With a Reduction of Days Crying Equal or More Than 50 Percent From Baseline — 6; 39 Participants — p=<0.0001
Phase 3 N=165 Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
Tick-Borne Encephalitis
Primary: Percentage of Seropositive Participants at 4 Weeks After Dose 3 — 98.0; 100 Percentage of participants
Phase 2 N=155 Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.50; -1.35 score on a scale
Phase 2 N=7 Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Astrocytoma, Grades II, III and IV · Glioblastoma Multiforme · Giant Cell Glioblastoma
Primary: Number of Participants With the Presence of Drug in the Tumor Tissue — 2 Participants
N/A N=50 INVEST Feasibility - Minimally Invasive Endoscopic Surgery With Apollo in Patients With Brain Hemorrhage
Intracranial Hemorrhage
Primary: Number of Participants Enrolled Within 730 Days of First Enrollment — 23 Participants